

REMARKS**STATUS OF THE CLAIMS**

Claims 1-5 were allowed according to the Notice of Allowability mailed November 30, 2005. Applicants request that claims 10-14 be added under 37 CFR § 1.312. Claims 1-5 are not amended in the present submission under 37 CFR § 1.312. were pending in the application.

The issue fee for this application has not yet been paid. Applicants request that the present amendments be entered as the proposed new claims are in compliance with the requirements of 37 C.F.R. § 1.312 and M.P.E.P. § 714.16 for its entry for the following reasons

The proposed new claims 10-14 are needed to provide a more proper scope of protection for the invention.

The proposed new claims 10-14 do not require any additional search or examination as they are supported by the specification as filed and recite “or a pharmaceutically acceptable salt thereof” instead of “or a pharmaceutically acceptable salt or ester form thereof.” in comparison to the allowed claims 1-5.

Claim 10 corresponds to allowed claim 1, except claim 10 recites “or a pharmaceutically acceptable salt thereof” and claim 1 recites “or a pharmaceutically acceptable salt or ester form thereof.”

Claim 11 corresponds to allowed claim 2, except claim 11 recites “or a pharmaceutically acceptable salt thereof” and claim 2 recites “or a pharmaceutically acceptable salt or ester form thereof.”

Claim 12 corresponds to allowed claim 3, except claim 12 recites “or a pharmaceutically acceptable salt thereof” and claim 3 recites “or a pharmaceutically acceptable salt or ester form thereof.”

Claim 13 corresponds to allowed claim 4, except claim 13 recites “or a pharmaceutically acceptable salt thereof” and claim 4 recites “or a pharmaceutically acceptable salt or ester form thereof.”

Claim 14 corresponds to allowed claim 5, except claim 14 depends from claim 10 which recites "or a pharmaceutically acceptable salt thereof" and claim 5 depends from claim 1 which recites "or a pharmaceutically acceptable salt or ester form thereof."

Support for new claims 10-14 can be found in the specification as filed, for example at page 11, lines 21-25; page 12 lines 1, bridging to page 13, line 4; and in claims 1-5 as filed.

The claims are patentable as they correspond very closely to the allowed claims except the new claims recite "or a pharmaceutically acceptable salt thereof" and the allowed claims 1-5 recites "or a pharmaceutically acceptable salt or ester form thereof."


CONCLUSION

Please charge any fees due in connection with the filing of this response to our Deposit Account No. 23-0455. If a fee is required for an extension of time not accounted for above, such an extension is requested and the fee should also be charged to Deposit Account No. 23-0455.

If the Examiner believes that a telephone conference would expedite the prosecution of this application, please telephone the undersigned at 734-622-2095.

Respectfully submitted,

Dated: February 13, 2006


Eric J. Baude
Registration No. 47,413
Warner-Lambert Company
2800 Plymouth Road
Ann Arbor, MI 48105
Telephone: (734) 622-2095
Facsimile: (734) 622-1553